Sharma Hari Shanker, Muresanu Dafin F, Castellani Rudy J, Nozari Ala, Lafuente José Vicente, Tian Z Ryan, Ozkizilcik Asya, Manzhulo Igor, Mössler Herbert, Sharma Aruna
International Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.
Department of Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania; "RoNeuro" Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania.
Prog Brain Res. 2019;245:145-200. doi: 10.1016/bs.pbr.2019.03.009. Epub 2019 Apr 2.
Alzheimer's disease (AD) is estimated to be afflicting over 55 millions of individual worldwide in 2018-19 for which no suitable clinical therapeutic measures have been developed so far. Thus, there is an urgent need to explore novel therapeutic strategies using nanodelivery of drugs and agents either alone or in combination for superior neuroprotection in AD and enhanced quality of life of the affected individuals. There are reports that AD is often associated with diminished neurotrophic factors and neprilysin together with enhancement of phosphorylated Tau (p-Tau) within the brain and in the cerebrospinal fluid (CSF). Thus, studies aiming to enhance neurotrophic factors and neprilysin together with neutralizing p-Tau within the central nervous system (CNS) may alleviate brain pathology in AD. In this review these strategies are discussed using nanotechnological approaches largely based on our own investigations in relation to current literature in the field.
据估计，2018 - 2019年全球有超过5500万人患有阿尔茨海默病（AD），目前尚未开发出合适的临床治疗措施。因此，迫切需要探索使用纳米药物递送单独或联合药物和制剂的新型治疗策略，以在AD中实现卓越的神经保护并提高受影响个体的生活质量。有报道称，AD通常与神经营养因子和中性内肽酶减少以及脑内和脑脊液（CSF）中磷酸化tau蛋白（p-Tau）增加有关。因此，旨在增强神经营养因子和中性内肽酶并中和中枢神经系统（CNS）中p-Tau的研究可能会减轻AD的脑病理。在这篇综述中，这些策略主要基于我们自己的研究并结合该领域的当前文献，使用纳米技术方法进行讨论。
